Abstract
The clinical efficacy, safety and utility of cefozopran (CZOP), a new eephem antibiotic, were evaluated in chronic respiratory infections in a comparative study versus ceftazidime (CAZ), Each drug was administered by intravenous drip infusion at a dose of 1.0 g (potency), twice daily for 14 days, and the forllowing results were obtained: 1. A total of 264 patients were enrolled in this study. Efficacy rates (“good” or better responses) were 91.0% (101/111) in the CZOP group and 88.3% (106/120) in the CAZ group, with no significant difference between the two groups. 2. Bacteriologically, eradication rates were 91.5% (65/71) in the CZOP group and 85.3% (64/ 75) in the CAZ group, with no significant difference between the two groups. 3. Adverse reactions occurred in 8 of the 122 patients in the CZOP group and in 3 of the 126 patients in the CAZ group. There was no significant difference between the two groups. The incidence of abnormal laboratory findings was 27.7% (33/119) in the CZOP group and 19.8% (25/ 126) in the CAZ group with no significant difference between the two groups. 4. The usefulness rates (“useful” or better evaluations) were 87.6% (99/113) in the CZOP group and 86.0% (104/121) in the CAZ group, with no significant difference between the two groups. No significant differences were observed between the two groups with respect to any of the above parameters. These results indicate that CZOP is useful for the treatment of chronic respiratory tract infections.
Original language | English |
---|---|
Pages (from-to) | 989-1017 |
Number of pages | 29 |
Journal | CHEMOTHERAPY |
Volume | 41 |
Issue number | 9 |
DOIs | |
Publication status | Published - 1993 |
Externally published | Yes |
Keywords
- cefozopran
- ceftazidime
- chronic respiratory tract infection
- comparative study
ASJC Scopus subject areas
- Pharmacology (medical)
- Infectious Diseases
- Pharmacology
- Drug Discovery
- Oncology
Access to Document
Other files and links
Fingerprint
Dive into the research topics of 'A comparative study of cefozopran for chronic respiratory tract infections'. Together they form a unique fingerprint.Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS
A comparative study of cefozopran for chronic respiratory tract infections. / Kobayashi, Hiroyuki; Kawai, Shin; Onodera, Sokichi; Nakano, Hitoshi; Tsuji, Tadakatsu; Maruyama, Junichi; Shimizu, Tetsuo; Sasaki, Nobuhiro; Yamaguchi, Shuji; Ohki, Yasuo; Nishigaki, Yutaka; Saito, Akira; Tomizawa, Masumi; Hiraga, Yohmei; Ohmichi, Mitsuhide; Terai, Tsugio; Yoshikawa, Takashi; Iida, Yasuto; Kato, Kazuyuki; Yashima, Hidenori; Takebe, Kazuo; Masuda, Mitsuo; Murakami, Seiichi; Matsukawa, Masakatsu; Osonoi, Ken; Tamura, Masashi; Konishi, Kazuki; Obara, Kazuo; Katagiri, Osamu; Yoshida, Taiji; Sato, Masao; Takishima, Tamotsu; Tanno, Yasuo; Motomiya, Masakichi; Watanabe, Akira; Tokue, Yutaka; Sato, Kazuo; Takizawa, Shigeo; Nakamura, Mikae; Arakawa, Masaaki; Wada, Kohichi; Iwata, Fumihide; Hoshino, Shigeyuki; Tsukata, Hiroki; Sekine, Osamu; Suzuki, Yasutoshi; Aoki, Nobuki; Takeda, Hazime; Sakai, Osamu; Shiba, Kohya; Okada, Kazuhisa; Nakamura, Hisao; Tanimoto, Hiroichi; Obara, Kazuo; Komatsuzaki, Katsumi; Tanabe, Osamu; Shimada, Kaoru; Sano, Yasuyuki; Arai, Yasuo; Inamatsu, Takashi; Koyama, Masaru; Nakata, Kohichiro; Narui, Kohji; Hayashi, Izumi; Ikemoto, Hideo; Shishido, Harumi; Watanabe, Hisashi; Shimada, Jingoro; Hori, Seiji; Matsumoto, Fumio; Imai, Takeo; Odagiri, Shigeki; Ogura, Takashi; Sumitomo, Midori; Yoshiike, Yasuhiro; Hirai, Yoshihiro; Hagiwara, Eri; Sakuma, Takashi; Irimajiri, Shoichiro; Mita, Seiji; Okubo, Takao; Ikeda, Hirotada; Murakoshi, Yoshiki; Kudo, Makoto; Tani, Kenji; Kaneko, Tamotsu; Nakamura, Toshio; Iwabuchi, Toshiki; Hasegawa, Hideyuki; Nakamura, Masao; Shoji, Akira; Sato, Atsuhiko; Chida, Kingo; Imokawa, Shiro; Suganuma, Hideki; Tamura, Ryoji; Yagi, Takeshi; Okano, Masahiko; Akiyama, Jinichiro; Taniguchi, Masami; Kita, Noriko; Okano, Hirokazu; Takeuchi, Toshihiko; Yamada, Yasuo; Yamamoto, Toshinobu; Hanaki, Hidekazu; Takeyama, Shinji; Hayashi, Yoshimitsu; Yamamoto, Kazuhide; Kato, Hiromi; Kobayashi, Tadashi; Uno, Tatsuto; Suzuki, Hidehiko; Izumi, Takateru; Nishimura, Koich; Koyama, Hiroshi; Fujimura, Naoki; Hamamoto, Kohei; Asamoto, Hitoshi; Ueda, Yoshihiro; Narita, Nobuhiro; Sawaki, Masayoshi; Mikasa, Keiichi; Mikia, Fumio; Kobayashi, Takehiko; Soejima, Rinzo; Niki, Yoshihito; Sumi, Masaru; Moriya, Osamu; Matsushima, Toshiharu; Kimura, Makoto; Sasaki, Takao; Matsumoto, Yukio; Sugimoto, Yuji; Yamakido, Michiro; Hasegawa, Kenji; Isobe, Takeshi; Kurimura, Tohru; Hiramoto, Takahiko; Takeda, Kohji; Toyofuku, Mamoru; Sawae, Yoshiro; Fukuma, Michio; Nakajima, Shinji; Ito, Takashi; Takaki, Koji; Ninomiya, Kiyoshi; Kumagai, Yukiko; Ohizumi, Kotaro; Ichikawa, Yoichiro; Tokunaga, Naoto; Ide, Soichirou; Kawahara, Masashi; Shigematsu, Hironari; Nagata, Akira; Fukuda, Yumi; Fujino, Kazuma; Tanaka, Fumio; Furuno, Hiroaki; Mitsutake, Yoshiyuki; Ishii, Kozo; Hara, Kohei; Kohno, Shigeru; Koga, Hironobu; Yatsugi, Masato; Sasayama, Kazuo; Ito, Naomi; Okuno, Kazuhiro; Fukushima, Kiyoyasu; Ishizaki, Akira; Watanabe, Koichi; Ishino, Tohru; Inoue, Yuichi; Asai, Sadahiro; Suyama, Naofumi; Mashimoto, Hideo; Matsumoto, Keizo; Nagatake, Takeshi; Takahashi, Atsushi; Hirose, Hidehiko; Ikeda, Yoshihiko; Morito, Toshihiro; Yoshimine, Hiroyuki; Tanaka, Hiroshi; Rikitomi, Naoto; Sakamoto, Tasuku; Takasugi, Masakazu; Degawa, Satoshi; Taguchi, Mikio; Yamamoto, Masashi; Shima, Kiyoshi; Takenaka, Shinobu; Hirata, Nahomi; Matsukura, Shigeru; Doutsu, Yasumasa; Ashitani, Junichi; Nasu, Masaru; Yamazaki, Tohru; Goto, Yoichiro; Nagai, Hiroyuki; Tashiro, Takayoshi; Goto, Jun; Kitagawa, Kazuo; Urakami, Saburo; Nagaoka, Hiroshi; Saito, Atsushi; Shigeno, Yoshiteru; Irabu, Yuei; Fukuhara, Hiroshi; Kusano, Nobuchika; Futenma, Mitsuhiko; Kitagawa, Daishiro; Miyagi, Mamoru; Teruya, Hiroshi; Ogawa, Nobuya; Kaku, Mitsuo; Sugawara, Kazuyuki.
In: CHEMOTHERAPY, Vol. 41, No. 9, 1993, p. 989-1017.Research output: Contribution to journal › Article › peer-review
}
TY - JOUR
T1 - A comparative study of cefozopran for chronic respiratory tract infections
AU - Kobayashi, Hiroyuki
AU - Kawai, Shin
AU - Onodera, Sokichi
AU - Nakano, Hitoshi
AU - Tsuji, Tadakatsu
AU - Maruyama, Junichi
AU - Shimizu, Tetsuo
AU - Sasaki, Nobuhiro
AU - Yamaguchi, Shuji
AU - Ohki, Yasuo
AU - Nishigaki, Yutaka
AU - Saito, Akira
AU - Tomizawa, Masumi
AU - Hiraga, Yohmei
AU - Ohmichi, Mitsuhide
AU - Terai, Tsugio
AU - Yoshikawa, Takashi
AU - Iida, Yasuto
AU - Kato, Kazuyuki
AU - Yashima, Hidenori
AU - Takebe, Kazuo
AU - Masuda, Mitsuo
AU - Murakami, Seiichi
AU - Matsukawa, Masakatsu
AU - Osonoi, Ken
AU - Tamura, Masashi
AU - Konishi, Kazuki
AU - Obara, Kazuo
AU - Katagiri, Osamu
AU - Yoshida, Taiji
AU - Sato, Masao
AU - Takishima, Tamotsu
AU - Tanno, Yasuo
AU - Motomiya, Masakichi
AU - Watanabe, Akira
AU - Tokue, Yutaka
AU - Sato, Kazuo
AU - Takizawa, Shigeo
AU - Nakamura, Mikae
AU - Arakawa, Masaaki
AU - Wada, Kohichi
AU - Iwata, Fumihide
AU - Hoshino, Shigeyuki
AU - Tsukata, Hiroki
AU - Sekine, Osamu
AU - Suzuki, Yasutoshi
AU - Aoki, Nobuki
AU - Takeda, Hazime
AU - Sakai, Osamu
AU - Shiba, Kohya
AU - Okada, Kazuhisa
AU - Nakamura, Hisao
AU - Tanimoto, Hiroichi
AU - Obara, Kazuo
AU - Komatsuzaki, Katsumi
AU - Tanabe, Osamu
AU - Shimada, Kaoru
AU - Sano, Yasuyuki
AU - Arai, Yasuo
AU - Inamatsu, Takashi
AU - Koyama, Masaru
AU - Nakata, Kohichiro
AU - Narui, Kohji
AU - Hayashi, Izumi
AU - Ikemoto, Hideo
AU - Shishido, Harumi
AU - Watanabe, Hisashi
AU - Shimada, Jingoro
AU - Hori, Seiji
AU - Matsumoto, Fumio
AU - Imai, Takeo
AU - Odagiri, Shigeki
AU - Ogura, Takashi
AU - Sumitomo, Midori
AU - Yoshiike, Yasuhiro
AU - Hirai, Yoshihiro
AU - Hagiwara, Eri
AU - Sakuma, Takashi
AU - Irimajiri, Shoichiro
AU - Mita, Seiji
AU - Okubo, Takao
AU - Ikeda, Hirotada
AU - Murakoshi, Yoshiki
AU - Kudo, Makoto
AU - Tani, Kenji
AU - Kaneko, Tamotsu
AU - Nakamura, Toshio
AU - Iwabuchi, Toshiki
AU - Hasegawa, Hideyuki
AU - Nakamura, Masao
AU - Shoji, Akira
AU - Sato, Atsuhiko
AU - Chida, Kingo
AU - Imokawa, Shiro
AU - Suganuma, Hideki
AU - Tamura, Ryoji
AU - Yagi, Takeshi
AU - Okano, Masahiko
AU - Akiyama, Jinichiro
AU - Taniguchi, Masami
AU - Kita, Noriko
AU - Okano, Hirokazu
AU - Takeuchi, Toshihiko
AU - Yamada, Yasuo
AU - Yamamoto, Toshinobu
AU - Hanaki, Hidekazu
AU - Takeyama, Shinji
AU - Hayashi, Yoshimitsu
AU - Yamamoto, Kazuhide
AU - Kato, Hiromi
AU - Kobayashi, Tadashi
AU - Uno, Tatsuto
AU - Suzuki, Hidehiko
AU - Izumi, Takateru
AU - Nishimura, Koich
AU - Koyama, Hiroshi
AU - Fujimura, Naoki
AU - Hamamoto, Kohei
AU - Asamoto, Hitoshi
AU - Ueda, Yoshihiro
AU - Narita, Nobuhiro
AU - Sawaki, Masayoshi
AU - Mikasa, Keiichi
AU - Mikia, Fumio
AU - Kobayashi, Takehiko
AU - Soejima, Rinzo
AU - Niki, Yoshihito
AU - Sumi, Masaru
AU - Moriya, Osamu
AU - Matsushima, Toshiharu
AU - Kimura, Makoto
AU - Sasaki, Takao
AU - Matsumoto, Yukio
AU - Sugimoto, Yuji
AU - Yamakido, Michiro
AU - Hasegawa, Kenji
AU - Isobe, Takeshi
AU - Kurimura, Tohru
AU - Hiramoto, Takahiko
AU - Takeda, Kohji
AU - Toyofuku, Mamoru
AU - Sawae, Yoshiro
AU - Fukuma, Michio
AU - Nakajima, Shinji
AU - Ito, Takashi
AU - Takaki, Koji
AU - Ninomiya, Kiyoshi
AU - Kumagai, Yukiko
AU - Ohizumi, Kotaro
AU - Ichikawa, Yoichiro
AU - Tokunaga, Naoto
AU - Ide, Soichirou
AU - Kawahara, Masashi
AU - Shigematsu, Hironari
AU - Nagata, Akira
AU - Fukuda, Yumi
AU - Fujino, Kazuma
AU - Tanaka, Fumio
AU - Furuno, Hiroaki
AU - Mitsutake, Yoshiyuki
AU - Ishii, Kozo
AU - Hara, Kohei
AU - Kohno, Shigeru
AU - Koga, Hironobu
AU - Yatsugi, Masato
AU - Sasayama, Kazuo
AU - Ito, Naomi
AU - Okuno, Kazuhiro
AU - Fukushima, Kiyoyasu
AU - Ishizaki, Akira
AU - Watanabe, Koichi
AU - Ishino, Tohru
AU - Inoue, Yuichi
AU - Asai, Sadahiro
AU - Suyama, Naofumi
AU - Mashimoto, Hideo
AU - Matsumoto, Keizo
AU - Nagatake, Takeshi
AU - Takahashi, Atsushi
AU - Hirose, Hidehiko
AU - Ikeda, Yoshihiko
AU - Morito, Toshihiro
AU - Yoshimine, Hiroyuki
AU - Tanaka, Hiroshi
AU - Rikitomi, Naoto
AU - Sakamoto, Tasuku
AU - Takasugi, Masakazu
AU - Degawa, Satoshi
AU - Taguchi, Mikio
AU - Yamamoto, Masashi
AU - Shima, Kiyoshi
AU - Takenaka, Shinobu
AU - Hirata, Nahomi
AU - Matsukura, Shigeru
AU - Doutsu, Yasumasa
AU - Ashitani, Junichi
AU - Nasu, Masaru
AU - Yamazaki, Tohru
AU - Goto, Yoichiro
AU - Nagai, Hiroyuki
AU - Tashiro, Takayoshi
AU - Goto, Jun
AU - Kitagawa, Kazuo
AU - Urakami, Saburo
AU - Nagaoka, Hiroshi
AU - Saito, Atsushi
AU - Shigeno, Yoshiteru
AU - Irabu, Yuei
AU - Fukuhara, Hiroshi
AU - Kusano, Nobuchika
AU - Futenma, Mitsuhiko
AU - Kitagawa, Daishiro
AU - Miyagi, Mamoru
AU - Teruya, Hiroshi
AU - Ogawa, Nobuya
AU - Kaku, Mitsuo
AU - Sugawara, Kazuyuki
PY - 1993
Y1 - 1993
N2 - The clinical efficacy, safety and utility of cefozopran (CZOP), a new eephem antibiotic, were evaluated in chronic respiratory infections in a comparative study versus ceftazidime (CAZ), Each drug was administered by intravenous drip infusion at a dose of 1.0 g (potency), twice daily for 14 days, and the forllowing results were obtained: 1. A total of 264 patients were enrolled in this study. Efficacy rates (“good” or better responses) were 91.0% (101/111) in the CZOP group and 88.3% (106/120) in the CAZ group, with no significant difference between the two groups. 2. Bacteriologically, eradication rates were 91.5% (65/71) in the CZOP group and 85.3% (64/ 75) in the CAZ group, with no significant difference between the two groups. 3. Adverse reactions occurred in 8 of the 122 patients in the CZOP group and in 3 of the 126 patients in the CAZ group. There was no significant difference between the two groups. The incidence of abnormal laboratory findings was 27.7% (33/119) in the CZOP group and 19.8% (25/ 126) in the CAZ group with no significant difference between the two groups. 4. The usefulness rates (“useful” or better evaluations) were 87.6% (99/113) in the CZOP group and 86.0% (104/121) in the CAZ group, with no significant difference between the two groups. No significant differences were observed between the two groups with respect to any of the above parameters. These results indicate that CZOP is useful for the treatment of chronic respiratory tract infections.
AB - The clinical efficacy, safety and utility of cefozopran (CZOP), a new eephem antibiotic, were evaluated in chronic respiratory infections in a comparative study versus ceftazidime (CAZ), Each drug was administered by intravenous drip infusion at a dose of 1.0 g (potency), twice daily for 14 days, and the forllowing results were obtained: 1. A total of 264 patients were enrolled in this study. Efficacy rates (“good” or better responses) were 91.0% (101/111) in the CZOP group and 88.3% (106/120) in the CAZ group, with no significant difference between the two groups. 2. Bacteriologically, eradication rates were 91.5% (65/71) in the CZOP group and 85.3% (64/ 75) in the CAZ group, with no significant difference between the two groups. 3. Adverse reactions occurred in 8 of the 122 patients in the CZOP group and in 3 of the 126 patients in the CAZ group. There was no significant difference between the two groups. The incidence of abnormal laboratory findings was 27.7% (33/119) in the CZOP group and 19.8% (25/ 126) in the CAZ group with no significant difference between the two groups. 4. The usefulness rates (“useful” or better evaluations) were 87.6% (99/113) in the CZOP group and 86.0% (104/121) in the CAZ group, with no significant difference between the two groups. No significant differences were observed between the two groups with respect to any of the above parameters. These results indicate that CZOP is useful for the treatment of chronic respiratory tract infections.
KW - cefozopran
KW - ceftazidime
KW - chronic respiratory tract infection
KW - comparative study
UR - http://www.scopus.com/inward/record.url?scp=0027453876&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0027453876&partnerID=8YFLogxK
U2 - 10.11250/chemotherapy1953.41.989
DO - 10.11250/chemotherapy1953.41.989
M3 - Article
AN - SCOPUS:0027453876
VL - 41
SP - 989
EP - 1017
JO - Chemotherapy
JF - Chemotherapy
SN - 0009-3165
IS - 9
ER -